[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 3 of about 3
1. Katz MH, Takimoto S, Spivack D, Moossa AR, Hoffman RM, Bouvet M: An imageable highly metastatic orthotopic red fluorescent protein model of pancreatic cancer. Clin Exp Metastasis; 2004;21(1):7-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An imageable highly metastatic orthotopic red fluorescent protein model of pancreatic cancer.
  • In order to investigate the antitumor and antimetastatic efficacy of new chemotherapeutic agents, a novel, red-fluorescent, orthotopic model of pancreatic cancer was constructed in nude mice.
  • Fluorescent tumor fragments were then transplanted onto the pancreas by surgical orthotopic implantation (SOI), facilitating high-resolution, real-time visualization of tumor and metastatic growth and dissemination in vivo.
  • Tumor growth at the primary site was visible within the first postoperative week, while distant metastasis and the development of ascites became visible over the following week.
  • This MIA-PaCa-2-RFP model produced extensive local disease and metastases to the retroperitoneum (100%), spleen (100%), intestinal and periportal lymph nodes (100%), liver (40%) and diaphragm (80%), and gave rise to malignant ascites and peritoneal carcinomatosis in 80% of cases.
  • Growth and metastasis of tumor was more rapid and frequent than in previously described orthotopic pancreatic cancer models, leading to a median survival of only 21 days after tumor implantation.
  • This unique, red fluorescent model rapidly and reliably simulates the highly aggressive course of human pancreatic cancer and can be easily non-invasively visualized in the live animal.
  • [MeSH-major] Luminescent Proteins / metabolism. Neoplasm Metastasis. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Animals. Cell Line, Tumor. Humans. Male. Mice. Mice, Nude. Neoplasm Transplantation. Survival Rate

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 2001 Mar;8(2):123-32 [11258776.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Feb 1;97(3):1206-11 [10655509.001]
  • [Cites] Pancreas. 2000 Mar;20(2):152-7 [10707930.001]
  • [Cites] Lancet Oncol. 2002 Sep;3(9):546-56 [12217792.001]
  • [Cites] CA Cancer J Clin. 2002 Jan-Feb;52(1):23-47 [11814064.001]
  • [Cites] Am J Surg. 2000 Jul;180(1):13-7 [11036132.001]
  • [Cites] Nat Biotechnol. 1999 Oct;17(10):969-73 [10504696.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5645-9 [1608975.001]
  • [Cites] Anticancer Res. 1993 May-Jun;13(3):627-30 [8391244.001]
  • [Cites] Cancer Res. 1998 Jun 1;58(11):2288-92 [9622060.001]
  • [Cites] Surgery. 1999 Sep;126(3):562-7 [10486610.001]
  • [Cites] Ann Surg. 1997 Sep;226(3):248-57; discussion 257-60 [9339931.001]
  • [Cites] J Am Coll Surg. 1999 Jul;189(1):1-7 [10401733.001]
  • [Cites] Pancreas. 2001 Oct;23(3):227-35 [11590317.001]
  • [Cites] Cancer Res. 2002 Mar 1;62(5):1534-40 [11888932.001]
  • [Cites] Cancer Res. 1996 Dec 15;56(24):5713-9 [8971180.001]
  • [Cites] Clin Exp Metastasis. 2000;18(3):213-8 [11315094.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3824-9 [11891294.001]
  • (PMID = 15065597.001).
  • [ISSN] 0262-0898
  • [Journal-full-title] Clinical & experimental metastasis
  • [ISO-abbreviation] Clin. Exp. Metastasis
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA23100-1851; United States / PHS HHS / / R43-89779
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Luminescent Proteins; 0 / red fluorescent protein
  •  go-up   go-down


2. Luz MA, Kotb AF, Aldousari S, Brimo F, Tanguay S, Kassouf W, Aprikian AG: Retroperitoneal lymph node dissection for residual masses after chemotherapy in nonseminomatous germ cell testicular tumor. World J Surg Oncol; 2010;8:97
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retroperitoneal lymph node dissection for residual masses after chemotherapy in nonseminomatous germ cell testicular tumor.
  • BACKGROUND: Retroperitoneal lymph node dissection has been advocated for the management of post-chemotherapy (PC-RPLND) residual masses of non-seminomatous germ cell tumors of the testis (NSGCT).
  • Between 1994 and 2008, three surgeons operated 73 patients with residual masses after cisplatin-based chemotherapy for a metastatic testicular cancer.
  • Patients needed to have normal postchemotherapy serum tumor markers, no prior surgical attempts to resect retroperitoneal masses and resectable retroperitoneal tumor mass at surgery to be included in this analysis RESULTS: Mean age was 30.4 years old.
  • The mean size of retroperitoneal metastasis was 6.3 and 4.0 cm, before and post-chemotherapy, respectively.
  • [MeSH-minor] Adolescent. Adult. Diagnosis, Differential. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasms, Germ Cell and Embryonal / drug therapy. Neoplasms, Germ Cell and Embryonal / secondary. Neoplasms, Germ Cell and Embryonal / surgery. Retroperitoneal Space. Retrospective Studies. Tomography, X-Ray Computed. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Nonseminomatous germ cell tumor.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urol Clin North Am. 1998 Aug;25(3):479-84 [9728217.001]
  • [Cites] Semin Oncol. 1998 Apr;25(2):203-9 [9562453.001]
  • [Cites] Cancer. 2007 Sep 15;110(6):1235-40 [17665498.001]
  • [Cites] J Urol. 2009 May;181(5):2097-101; discussion 2101-2 [19286227.001]
  • [Cites] Health Rep. 2009 Mar;20(1):7-19 [19388364.001]
  • [Cites] Urol Oncol. 2009 Jul-Aug;27(4):417-21 [19573772.001]
  • [Cites] BJU Int. 2009 Nov;104(9 Pt B):1404-12 [19840021.001]
  • [Cites] Urol Oncol. 2010 Sep-Oct;28(5):504-9 [19097812.001]
  • [Cites] J Urol. 2001 May;165(5):1517-20 [11342909.001]
  • [Cites] Cancer. 2002 Mar 15;94(6):1668-76 [11920527.001]
  • [Cites] BJU Int. 2002 Apr;89(6):549-56 [11942962.001]
  • [Cites] Br J Cancer. 2003 Mar 24;88(6):843-7 [12644820.001]
  • [Cites] Ann Surg. 2004 Aug;240(2):205-13 [15273542.001]
  • [Cites] Ann Oncol. 2004 Sep;15(9):1377-99 [15319245.001]
  • [Cites] Cancer. 1994 Aug 15;74(4):1329-34 [8055456.001]
  • [Cites] J Urol. 1995 Mar;153(3 Pt 2):976-80 [7853586.001]
  • [Cites] J Urol. 1995 Oct;154(4):1373-5 [7544838.001]
  • [Cites] J Urol. 1996 Nov;156(5):1656-8 [8863564.001]
  • [Cites] Eur J Cancer. 1997 May;33(6):843-7 [9291803.001]
  • [Cites] Cancer. 1998 Oct 1;83(7):1409-19 [9762943.001]
  • (PMID = 21062470.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] Nonseminomatous germ cell tumor
  • [Other-IDs] NLM/ PMC2991320
  •  go-up   go-down


Advertisement
3. Okayama S, Matsui M, Somekawa S, Iwano M, Saito Y: Non-contrast MRI for the evaluation of hydronephrotic and dysfunctioning kidney secondary to testicular cancer. Ren Fail; 2009;31(2):153-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-contrast MRI for the evaluation of hydronephrotic and dysfunctioning kidney secondary to testicular cancer.
  • Gadolinium-containing magnetic resonance imaging (MRI) contrast agents have been reported to induce nephrogenic systemic fibrosis in patients with renal dysfunction, and therefore their use has been restricted.
  • However, even without contrast agents, MRI can provide much valuable information on the pathophysiology of renal diseases.
  • This report describes the case of a 90-year-old man with a hydronephrotic and dysfunctioning right kidney induced by testicular cancer evaluated by non-contrast MRI.
  • Moreover, a retroperitoneal metastatic tumor was detected adjacent to the right kidney, which appeared to constrict the right urinary duct.
  • These findings clarified that the retroperitoneal metastasis from the right testicular cancer led to hydronephrosis and dysfunctioning of the right kidney.
  • [MeSH-major] Contrast Media / contraindications. Hydronephrosis / diagnosis. Testicular Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19212914.001).
  • [ISSN] 1525-6049
  • [Journal-full-title] Renal failure
  • [ISO-abbreviation] Ren Fail
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down






Advertisement